Archemix Corporation
148 Sidney Street
Cambridge
Massachusetts
02139
United States
Tel: 617-621-7700
Fax: 617-621-9300
Website: http://www.archemix.com/
Email: info@archemix.com
41 articles about Archemix Corporation
-
Archemix Corporation Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Nuvelo, Inc.
1/30/2008
-
Archemix Corporation Announces Initiation of Phase 2a Trial for Aptamer Product Candidate ARC1779 in Patients with Acute Coronary Syndrome
11/13/2007
-
Archemix Corporation and SomaLogic Expand Strategic Alliance
8/8/2007
-
Archemix Corporation and Isis Pharmaceuticals, Inc. (Jobs) Form Strategic Alliance for Aptamer Drug Discovery and Development
8/8/2007
-
Archemix Corporation and Takeda Pharmaceutical Co. Ltd. (Jobs) to Enter into Collaboration for Discovery and Development of Aptamer Therapeutics
6/11/2007
-
Archemix Corporation Announces Completion of Phase 1 Trial of ARC1779
6/8/2007
-
Robert B. Stein, M.D., Ph.D., Joins Archemix Corporation Board of Directors
4/3/2007
-
Archemix Corporation is Granted Two European Patents for the Identification and Use of Therapeutic Aptamers
3/8/2007
-
Archemix Corporation And Merck KGaA To Collaborate On Aptamer-Based Cancer Therapeutics; Archemix Will Receive As Much As $10 Million
1/17/2007
-
Archemix Corporation Announces Collaboration With Pfizer Inc. To Discover Aptamer Therapeutics
1/9/2007
-
Archemix Corporation Announces Initiation Of Phase I Clinical Trial For Novel, Selective Anti-Platelet Aptamer (ARC1779)
1/3/2007
-
Archemix Corporation Appoints Industry Expert James McArdle, Ph.D., As Vice President, CMC
12/4/2006
-
Archemix Corporation Grants Ribomic A License To Its Intellectual Property To Develop And Commercialize Aptamer-Based Reagents
11/29/2006
-
Archemix Corporation CEO To Present At The Biotechnology Industry Organization (BIO) Investor Forum 2006
10/16/2006
-
Archemix Corporation Strengthens Management With Appointment Of James Gilbert, M.D., As Chief Medical Officer
10/3/2006
-
The Day In Review: Nuvelo, Inc. Expands Archemix Corporation Deal
8/1/2006
-
Archemix Corporation And Nuvelo, Inc. Expand Collaboration And Nominate New Clinical Compound
8/1/2006
-
Archemix Corporation Announces Strategic Alliance With Elan Corporation PLC To Discover And Develop Aptamer Therapeutics
7/13/2006
-
Archemix Corporation Strengthens Its Board Of Directors Adding Alnylam Pharmaceuticals President And CEO, John Maraganore, Ph.D.
5/31/2006
-
Archemix Corporation Moves To New Headquarters In Cambridge, Mass.
2/10/2006